PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.14
D/E of 0.14 while GNPX has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
4.63
Dangerously higher net debt above 1.5x GNPX's 0.29. Jim Chanos would check for potential debt spiral risks.
-3518.20
Negative coverage while GNPX shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
1.20
Current ratio 1.25-1.5x GNPX's 0.84. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.